Endometrial cancer risk in estrogen users after switching to estrogen–progestin therapy
- 25 July 2007
- journal article
- Published by Springer Science and Business Media LLC in Cancer Causes & Control
- Vol. 18 (9), 1001-1007
- https://doi.org/10.1007/s10552-007-9040-6
Abstract
It is unknown whether postmenopausal unopposed estrogen users are better off, in terms of endometrial cancer risk, switching to a combined estrogen-progestin regimen or stopping hormone use altogether. We analyzed data from a series of three population-based case-control studies in western Washington state during 1985-1999, comparing proportions of "switchers" and "stoppers" in cases and controls. We also assessed whether the risk of endometrial cancer in either group of former unopposed estrogen users returned to that of never users. After multivariate adjustment using unconditional logistic regression, women who switched to a combined regimen with a progestin added for at least ten days/month (37 cases, 47 controls) had half the risk of endometrial cancer of women who stopped hormone use altogether (86 cases, 78 controls) (adjusted odds ratio = 0.5, 95% confidence interval: 0.3-1.1). Most subgroups of former users, whether they switched or stopped, had some increased risk of endometrial cancer compared to never users. Results from this study suggest that unopposed estrogen users may reduce their risk of endometrial cancer more by switching to a combined regimen with progestin added for at least ten days/month than by stopping hormone use altogether.Keywords
This publication has 22 references indexed in Scilit:
- Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancerAmerican Journal of Obstetrics and Gynecology, 2007
- Endometrial Carcinoma Risks among Menopausal Estrogen plus Progestin and Unopposed Estrogen Users in a Cohort of Postmenopausal WomenCancer Epidemiology, Biomarkers & Prevention, 2005
- The NICHD Women's Contraceptive and Reproductive Experiences StudyAnnals of Epidemiology, 2002
- Endometrial CancerPublished by Elsevier BV ,2000
- Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens aloneAmerican Journal of Obstetrics and Gynecology, 1994
- Estrogen replacement therapy and the risk of endometrial cancer: Remaining controversiesAmerican Journal of Obstetrics and Gynecology, 1990
- The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasiaAmerican Journal of Obstetrics and Gynecology, 1989
- Climacteric Symptoms and Estrogen Replacement Therapy In Women with Endometrial CarcinomaActa Obstetricia et Gynecologica Scandinavica, 1986
- Risk of Localized and Widespread Endometrial Cancer in Relation to Recent and Discontinued Use of Conjugated EstrogensNew England Journal of Medicine, 1985
- Replacement Estrogens and Endometrial CancerNew England Journal of Medicine, 1979